Drug Interaction Between Buprenorphine and Alprazolam

Introduction to Critical Safety Considerations

The combination of buprenorphine and alprazolam substantially increases the risk of life-threatening respiratory depression, profound sedation, coma, and death by 3- to 10-fold compared to opioids alone, according to the American College of Medical Toxicology 1

Buprenorphine activates mu-opioid receptors on brainstem neurons controlling breathing, directly inducing respiratory depression, as noted by the National Institute on Drug Abuse 1
Alprazolam potentiates this effect through GABA-mediated mechanisms, increasing the risk of respiratory depression, as reported by the Substance Abuse and Mental Health Services Administration 1
The combination produces non-additive, synergistic respiratory depression that is greater than either drug alone, affecting inspiratory time, expiratory time, tidal volume, and diaphragm contraction amplitude, according to the American Academy of Sleep Medicine 1
Benzodiazepines were found in 31-61% of fatal opioid overdose deaths, highlighting the need for caution when prescribing these medications together, as warned by the Centers for Disease Control and Prevention 1

When concomitant use cannot be avoided, the American Medical Association recommends using the absolute lowest effective dosages of both medications and prescribing minimum durations of concomitant use 1
The American Society of Addiction Medicine suggests checking the Prescription Drug Monitoring Program (PDMP) for other controlled substances the patient is receiving, and involving pharmacists and pain specialists as part of the management team 2, 1
The National Institute on Drug Abuse advises counseling patients and caregivers about signs of respiratory depression, such as slow or shallow breathing, extreme drowsiness, and inability to wake, and warning patients to avoid alcohol and other CNS depressants 1

Elderly patients (≥65 years) have altered pharmacokinetics, reduced clearance, and smaller therapeutic window, and face substantially increased overdose risk, cognitive impairment, falls, and fractures, according to the American Geriatrics Society 1, 3
Patients with respiratory compromise, such as those with COPD, asthma, or sleep apnea, are at heightened risk of respiratory depression, and alternative treatments should be considered first, as recommended by the American Thoracic Society 1
Patients with substance use disorder are already at elevated baseline risk for overdose, and evidence-based treatment, such as medication-assisted treatment with behavioral therapies, should be offered, according to the Substance Abuse and Mental Health Services Administration 2

Instead of alprazolam, consider SSRIs, SNRIs, buspirone, or hydroxyzine as first-line options for anxiety management, as suggested by the American Psychiatric Association 1
Cognitive behavioral therapy (CBT) is an evidence-based psychotherapy that can be used to manage anxiety, according to the National Institute of Mental Health 2, 1
Optimizing the buprenorphine regimen through dose adjustment or opioid rotation can help reduce the risk of respiratory depression, as recommended by the American Society of Addiction Medicine 1

When tapering is needed, recent guidance recommends tapering benzodiazepines first due to higher withdrawal risks, though the 2016 CDC guideline suggested tapering opioids first, as noted by the Centers for Disease Control and Prevention 1, 3
Never abruptly discontinue benzodiazepines, as this can cause seizures and death, according to the American Medical Association 2, 1, 3
Reduce benzodiazepine dose by 10-25% of the current dose every 1-2 weeks, and integrate cognitive behavioral therapy during the taper to significantly increase success rates, as recommended by the Substance Abuse and Mental Health Services Administration 1, 3
Monitor patients at least monthly, with more frequent contact during difficult phases, according to the American Society of Addiction Medicine 1, 3